Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Exagamglogene Autotemcel is a Cell & Gene Therapy drug candidate, which is currently being evaluated in IND Enabling clinical studies for the treatment of Geographic Atrophy-associated with Macular Degeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 08, 2025
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Gimv
Deal Size : $78.9 million
Deal Type : Series A Financing
Details : With the financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related ma...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 17, 2023
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Gimv
Deal Size : $78.9 million
Deal Type : Series A Financing
Reset All
